Billionaire Ajay Piramal runs a
successful listed company in India. He has generated massive 26% returns for
his shareholders over the long term – 28 years to be precise. In the latest
annual report of his operating company, he talks about his thoughts of
generating long term value for shareholders in the future.
Following are the key takeaways
for investors from his latest annual report:
1. Virtual
Companies: Mr.Piramal’s operating company is currently in three businesses –
pharmaceuticals, information management and financial services. According to him,
they have now grouped these three businesses as three virtual companies. This
mindset has helped in a) execution discipline in the form of focus on achieving
near term goals, milestones and budgets in each of these virtual companies, and
b) Prioritization in use of available capital.
2. Efficient
Capital Allocation: The cornerstone of value creation is efficient capital
allocation. Piramal is committed to efficiently allocating capital while
undertaking controlled risk, to consistently generate higher profitability and
deliver superior shareholder returns. The company has undertaken various steps
during the year towards this like a) bolt-on acquisitions in different
businesses, b) enhanced minority stake in Shriram Group, c) Deleveraged balance
sheet, d) Returned capital to shareholders and e) Significantly scaled down the
high-risk high-reward New Chemical Entity Research Programme.
3. Partnerships:
Piramal highlights that he company is the first port of call for global majors
for partnerships in various businesses and co-investments. He highlights that since
its inception, they have practiced and maintained the highest standards of ethics,
integrity and corporate governance in each of its business dealings. The result
is that the company has forged relationships with global partners like CPPIB
(for co-investment in real estate funding), APG Asset Management (co-investment
in Infrastructure funding), Vodafone (historically invested in Vodafone India),
Abbott (sold pharma business to Abbott) and Allergan (has a local JV for
pharmaceutical business).
4. Minority
but ‘Strategic’ Investments: While Mr.Piramal’s about $700mn minority investments
in the Shriram Group appear passive, they have been repeatedly been referred to
as ‘Strategic’, along with the mention that Mr.Piramal is now the non-executive
chairman of Shriram Capital, the financial services holding company of Shriram
Group. Thus, there may be an intention to take active participation in these
minority investments in future.
Important quote from the annual report highlighting long term
shareholder value creation:
“Over the last three decades,
we have demonstrated our entrepreneurial abilities by allocating capital
efficiently in high-potential businesses and operating them well, thereby
creating long term value for our shareholders.
In 1988, we moved out of textiles and into pharmaceuticals through the acquisition
of the 48th ranked pharma company. Over the next two decades, we
transformed into a top 5 pharma company through both organic and inorganic
means. Five years ago, we sold our Domestic Formulations business at an
attractive valuation to Abbott to generate substantial value for our
stakeholders, a large part of which was returned through dividends and buyback.”